Combined cancer immunotherapy against aurora kinase A

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F16%3A00011530" target="_blank" >RIV/00023736:_____/16:00011530 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11310/16:10325982
Result on the web
<a href="http://dx.doi.org/10.1097/CJI.0000000000000120" target="_blank" >http://dx.doi.org/10.1097/CJI.0000000000000120</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/CJI.0000000000000120" target="_blank" >10.1097/CJI.0000000000000120</a>

Result language
angličtina
Original language name
Combined cancer immunotherapy against aurora kinase A
Original language description
Aurora kinase A (AURKA) is a centrosomal protein that is overexpressed in a number of human malignancies and can contribute to tumor progression. As we used this protein as a target of DNA immunization, we increased its immunogenicity by the addition of the PADRE helper epitope and decreased its potential oncogenicity by mutagenesis of the kinase domain. Our results suggest that combined cancer immunotherapy should be carefully evaluated to achieve the optimal antitumor effect.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)